

15TH STEERING COMMITTEE MEETING MEETING MINUTES

Date and venue: 3 June 2022, 09:00–11:00 CET, online meeting (videoconference)

Participants:

Martina Koziar Vašáková
Sanja Dimic Janjic
Nesrin Mogulkoc
Michael Studnicka
Anton Penev

Zoran Arsovski
Jakub Gregor
Klaus-Uwe Kirchgässler
Julia Spielhofer

Absent:

Marta Hájková
Mordechai Kramer
Katarzyna Lewandowska

Veronika Müller
Jasna Tekavec-Trkanjec

The meeting minutes are accompanied by the official presentation of the 15th SC meeting and summarise discussion from the 15th SC meeting.

Current state, contracts

- Refreshed communication with Romania in February – follow-up after the decision about the EMPIRE continuation (IBA)

Analyses & publications

- *Comorbidities (Jovanović)*: published in Respiratory Research
- *Long-term survival and switch (Adir, Koziar Vašáková)*: new analysis in June
- *Pirfenidone in diagnostic groups (Májek, Gregor, Koziar Vašáková)*: revised version reviewed again, there is another reviewer suggesting minor revision
- *Correlation of response to antifibrotic treatment with adverse events to antifibrotic drugs in IPF patients from the EMPIRE registry (Jovanović)*: analysis to be completed after investigator's initial review
- 6 analyses to be specified and initiated:
 - Crepitus: Michael Studnicka
Analysis to be specified by investigator (a new PhD student in autumn)
 - Quality of life: Katarzyna Lewandowska
Analysis to be specified by investigator
 - Genetics in Czech and Turkish cohorts: Nesrin Mogulkoć
Analysis to be specified by investigator, communication with Dr Kriegová to be continued with the support of Martina Koziar Vašáková. Inclusion of David Schwarz – Nesrin Mogulkoć
 - COVID-19 in IPF patients: Nesrin Mogulkoc
Analysis to be specified by investigator
Centres will be asked to complete information about COVID-19 infection in their patients and about their vaccination (IBA)

- Longitudinal weight change in IPF patients treated with antifibrotics: Nesrin Mogulkoc
Analysis to be specified by investigator
- Protective effect of antifibrotics against lung cancer: Nesrin Mogulkoc
Analysis to be specified by investigator

HRCT repository

- Launched in October using TatraMed software and services
- Two Czech hospitals (Hradec Králové, Brno) have signed the contract, others in negotiation (reminder) (IBA)
- Reminder to Warsaw and Budapest, contract proposal to be sent to Ege (IBA)

PD-L1 IIS

- Preparation of the study temporarily stopped with regard to uncertainties of prospective data collection (continuation of the EMPIRE registry and availability of clinical data)
- Ege University will investigate eventual analysis of PD-L1 in their samples in Turkey (commercial or research-based mode of collaboration) (Nesrin Mogulkoc)

Nintedanib IIS

- Analysis of short- and long-term clinical outcome of patients treated with nintedanib with different characteristics
- Investigator: Martina Koziar Vašáková
- To be completed in June

EMPIRE continuation after 2022

- Roche expressed their interest to support the registry with up to 100,000 EUR per year for 3 years
- BI still in discussion
- No funding from 1 July 2022. Full budget for EMPIRE has not been consumed to date – BI will examine ways to transfer remaining amount, which would be used for the reimbursement of data managers in Q3 (and eventually Q4) / 2022.
- Martina Koziar Vašáková and IBA will prepare a new version of the study protocol to reflect inclusion of other pulmonary fibroses

Summary of tasks for the next period

- **Piloting phase of the HRCT repository – IBA will approach centres from regarding contract amendment, continuous communication with centres that already received this proposal.**
- **Further phase of the Nintedanib IIS (analyses, interpretation, final report).**
- **Preparation of a new protocol**

The 16th Steering Committee will probably take place in Barcelona during ERS (early September 2022).

Drafted by: Jakub Gregor

Approved by: M. Koziar Vašáková